Clinical Advancement
We are advancing a focused portfolio of already-discovered antibody leads toward the clinic, with rigorous scientific planning and a small number of core programs as our primary strategic focus.
Antibody Platform. Discovery. Design.
Building the next generation of antibody innovation.
Sapia Bio is focused on advancing a portfolio of biologics, developing AI-enabled approaches for faster, more precise antibody design, and collaborating with partners to accelerate discovery and development.
About Us
Focused on biologics, discovery, and intelligent design.
Sapia Bio is being built around three complementary priorities: the development of a portfolio of antibody candidates against diverse targets, the creation of partner-ready discovery capabilities, and the application of advanced computational methods to accelerate antibody design.
Our intent is to build practical, high-value capabilities that support both internal program advancement and external collaboration across the antibody discovery ecosystem.
Portfolio
Antibody discovery and design capabilities built for collaboration.
Our capabilities are powered by complementary computational and high-throughput antibody screening platforms, giving us both the predictive design tools and the experimental scale to move candidates forward quickly.
AI-driven Discovery & Design
Our discovery engine combines AI-driven design and optimization with computational and high-throughput experimental screening, enabling faster, more precise identification of antibody candidates.
Discovery Partnerships
We partner with biotech and pharma collaborators, leveraging our discovery platforms and capabilities to support and accelerate external antibody programs.
Leadership
Your scientific collaborators, built around outcomes.
Perry Wasdin, PhD
Chief Executive Officer
Perry Wasdin, PhD
Chief Executive Officer
As CEO, Dr. Wasdin leads Sapia's overall strategy, operations, and business development. He is a Data Scientist at Vanderbilt University Medical Center and an inventor of the MAGE technology for AI antibody design, with expertise in machine learning and B cell immunology.
Ivelin Georgiev, PhD
Chief Scientific Officer
Ivelin Georgiev, PhD
Chief Scientific Officer
Dr. Georgiev leads translational strategy and the scientific design of clinical development programs. He is Director of the Vanderbilt Center for Computational Microbiology and Immunology and Professor of Pathology, Microbiology & Immunology and Computer Science at Vanderbilt, where his research focuses on antibody discovery and immunotherapy. He holds multiple patents, including antigen IP underlying an FDA-approved vaccine, and has extensive experience translating computational and immunological discoveries into therapeutic applications.
Contact
Let’s explore what’s next.
Get in touch with us to learn more about our portfolio, capabilities, and partnership opportunities.